Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience

被引：0
|
作者：
Feixas, Pablo Tenorio [1 ]
Cox, Catrin [1 ]
Peer, Xavier [1 ]
Cuthill, Kirsty [1 ]
Benjamin, Reuben [2 ]
Gunawan, Arief [2 ]
Cuadrado, Maria [1 ]
de Farias, Madson Correia [1 ]
Jones, John [1 ]
Shin, Jin-Sup [1 ]
Batool, Asma [1 ]
Bowcock, Stella [1 ]
Omer, Musab [1 ]
Tawde, Prachi [1 ]
Bailey, Katharine [1 ]
机构：
[1] Kings Coll Hosp NHS Fdn Trust, London, England
[2] Kings Coll Hosp London, London, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-087
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [21] Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
    Mohan, Meera
    Monge, Jorge
    Shah, Nishi
    Luan, Danny
    Forsberg, Mark
    Bhatlapenumarthi, Vineel
    Balev, Metodi
    Patwari, Anannya
    Cheruvalath, Heloise
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Dhakal, Binod
    Zangari, Maurizio
    Al-Hadidi, Samer
    Cooper, Dennis
    Lentzsch, Suzanne
    van Rhee, Frits
    D'Souza, Anita
    Szabo, Aniko
    Schinke, Carolina
    Chakraborty, Rajshekhar
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [22] Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gill, Sarvarinder Kaur
    Fleming, Erika
    Gebre, Helen
    Bangolo, Ayrton, I
    Siegel, David S.
    Vesole, David H.
    Biran, Noa
    Parmar, Harsh
    Phull, Pooja
    BLOOD, 2024, 144 : 7047 - 7048
  • [23] A German Multicenter Real-World Analysis of Talquetamab in 102 Patients With Relapsed/ Refractory Multiple Myeloma
    Frenking, Jan
    Riedhammer, Christine
    Besemer, Britta
    Braune, Jan
    Brioli, Annamaria
    Brunner, Franziska
    Dampmann, Maria
    Gezer, Deniz
    Goldman-Mazur, Sarah
    Haenel, Mathias
    Hanoun, Christine
    Hoegner, Marion
    Kolditz, Katja
    Kos, Igor
    Kull, Miriam
    Leitner, Theo
    Merz, Maximilan
    von Metzler, Ivana
    Michel, Christian S.
    Teipel, Raphael
    Theurich, Sebastian
    Waesch, Ralph
    Zukovs, Romans
    Rasche, Leo
    Raab, Marc-Steffen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S52 - S53
  • [24] Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma
    Tan, Carlyn Rose Co
    Derkach, Andriy
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather Jolie
    Giralt, Sergio
    Lesokhin, Alexander M.
    Korde, Neha
    Lin, Dee
    Wu, Bingcao
    Fowler, Jessica
    Fernandez, Mariana
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Krishnan, Amrita Y.
    Nooka, Ajay K.
    Chari, Ajai
    Garfall, Alfred L.
    Martin, Thomas G.
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Eric, Ammann
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok V.
    Slavcev, Mary
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Noga, S.
    Jhaveri, M.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    HAEMATOLOGICA, 2016, 101 : 538 - 539
  • [27] Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Kotowsky, Nirali
    Bitetti, Jacopo
    Mackay, Christine
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans C.
    BLOOD, 2022, 140 : 10124 - 10126
  • [28] Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Zhang, Shijia
    Richter, Joshua R.
    Kuo, Yen-Hong
    Schmidt, Linda
    McBride, Laura
    Anand, Palka
    Ivanovski, Kristin
    Pierre, Amy
    Kumka, Susan
    Cuccurullo, Carmela
    Siegel, David S.
    BLOOD, 2016, 128 (22)
  • [29] Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Shaikh, Hira
    Lochner, Jonathan
    Friend, Reed
    Snyder, Jordan
    Davis, James
    Patrus, Gina
    Dileo, Rachel
    Ahmed, Nausheen
    Mewawalla, Prerna
    Poonsombudlert, Kittika
    Struble, Emily
    Wolcott, Allyson
    Green, Kimberly
    Sparrow, Samantha
    Mushtaq, Muhammad Umair
    Paul, Barry
    Abdallah, Al-Ola
    Strouse, Christopher
    Hashmi, Hamza
    Atrash, Shebli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S87 - S88
  • [30] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Sannareddy, Aishwarya
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Khouri, Jack
    Kaur, Gurbakhash
    Strouse, Christopher
    Valent, Jason
    Larry, Anderson D., Jr.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
12345